Lucence Diagnostics Plasma EGFR C797S Mutation Detection Assay
Lucence Diagnostics has launched its plasma EGFR C797S non-invasive mutation detection assay for clinical use in Southeast Asia. The assay is based on Lucence's proprietary Lumi-ARMS technology, and rapidly detects the presence of the EGFR C797S mutation which is linked with osimertinib resistance in EGFR-mutant non-small cell lung cancer. The assay can be used with blood and cerebrospinal fluid and features a sensitivity of up to 0.01 percent, the company said. The assay is also currently available as part of the Lucence LiquidTrack test offered through the company's reference laboratory in Singapore.
OpGen Acuitas Gene Panel u.547 Test
OpGen has announced today the commercial availability of its Acuitas AMR Gene Panel u5.47 test. The research-use-only test was developed to detect the most common bacterial causes of complicated urinary tract infections from urine and isolated colonies. The gene panel also detects 47 gene targets that indicate antibiotic resistance. Test results are typically available in less than three hours compared to traditional microbiology methods, which require two to three days to produce results.
Synthego Inference of CRISPR Edits Software
Synthego has launched a new tool named Inference of CRISPR Edits, or ICE. This CRISPR analysis software features rapid, reproducible batch processing of Sanger data. It's also free to use and open source, according to the company. Featuring an easy-to-use interface, ICE provides insertion and deletion percentage, indel contributions, and total discordance against wild-type sequence data for up to hundreds of samples at a time, the company said.
For more new products and services, please visit the New Products page on our website.